Skip to main content

Advertisement

Table 1 Baseline patient characteristics

From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

  Arm A (n = 18) Arm B (n = 24) p-value
Clinical characteristics
 Female: n (%) 13 (72.2) 19 (79.2)
 Age: median (range) 63 (24–80) 65.5 (27–82)
 Radio-induced: n (%) 7 (38.9) 12 (50)
 Superficial: n (%)a 11 (61.1) 16 (66.7)
 Grade 2 or 3: n (%) 10 (55.6) 13 (54.2)
 Metastatic: n (%) 12 (66.7) 16 (66.7)
 Prior exposure to anthracycline: n (%) 8 (44.4) 8 (33.3)
 Performance status (WHO) = 0: n (%)b 10 (58.8) 13 (54.2)
Baseline biomarkers (D1)
 Human FGF (pg/mL): mean (sd) 5.6 (2.1) 6.0 (3.5) 0.72
 PlGF (pg/mL): mean (sd) 24.7 (17.2) 17.8 (10.2) 0.12
 SCF sR/c-kit (ng/mL): mean (sd) 8.9 (2.5) 8.2 (2.6) 0.35
 sE-Selectin (ng/mL): mean (sd) 33.7 (18.5) 44.8 (24.9) 0.08
 TSP-1 (μg/mL): mean (sd) 54.9 (17.3) 44.9 (21.6) 0.17
 VEGF (ng/mL): mean (sd) 0.44 (0.28) 0.55 (0.39) 0.38
 VEGF-C (ng/mL): mean (sd) 4.2 (1.5) 4.4 (1.7) 0.70
  1. aSuperficial angiosarcomas included 19 breast angiosarcomas, 5 skin angiosarcomas, 2 soft-tissue angiosarcomas and 1 scalp angiosarcoma
  2. bWHO World Health Organization